Heteroaryl Pyridazine Carboxamides For Cancer Treatment
Summary
The USPTO published patent application US20260098036A1 filed by Deutsches Krebsforschungszentrum covering 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds for cancer treatment. The application claims novel chemical compounds, methods of preparation, pharmaceutical compositions, and methods of treating cancer and disorders associated with aberrant AHR signaling.
What changed
The USPTO published patent application US20260098036A1 for novel heteroaryl pyridazine carboxamide compounds and their use in treating cancer and immune-related disorders. The application covers compounds of general formula (I), methods of preparing said compounds, pharmaceutical compositions, and combination therapies. The claimed compounds target AHR (aryl hydrocarbon receptor) signaling pathways.\n\nPharmaceutical companies developing AHR-targeted oncology therapeutics should review freedom-to-operate considerations. The German Cancer Research Center may seek licensing partners for co-development or commercialization of these compounds.
What to do next
- Monitor patent prosecution status
- Review freedom-to-operate for AHR-targeted cancer therapies
- Evaluate licensing opportunities
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER
Application US20260098036A1 Kind: A1 Apr 09, 2026
Assignee
Deutsches Krebsforschungszentrum
Inventors
Ilona GUTCHER, Ulrike RÖHN, Norbert SCHMEES, Ludwig ZORN, Lars RÖSE, Benjamin BADER, Christina KOBER, Rafael CARRETERO, Detlef STÖCKIGT, Horst IRLBACHER, Michael PLATTEN
Abstract
The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I): in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
CPC Classifications
C07D 417/04 A61K 31/501 A61K 31/506 A61K 45/06 A61P 35/00 C07D 237/14 C07D 401/04 C07D 401/14 C07D 403/04 C07D 405/14 C07D 409/04 C07D 409/14 C07D 413/04
Filing Date
2025-11-26
Application No.
19402587
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.